Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | PKLR | P30613 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | POLB | P06746 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7029089 | 0.87 | NPC1 (0.64) | LMNAKMT2AMEN1PKMNPC1 | |
| SCHEMBL19392346 | 0.85 | KMT2A (0.76) | KMT2AMEN1PKMPOLBL3MBTL1 | |
| SCHEMBL7025981 | 0.84 | LMNA (0.59) | LMNAKMT2AMEN1PKMNPC1 | |
| SCHEMBL7030304 | 0.84 | KMT2A (0.74) | LMNAKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL7023315 | 0.84 | KMT2A (0.78) | KMT2AMEN1ALDH1A1TSHRPOLB | |
| SCHEMBL13150788 | 0.83 | SIGMAR1 (0.88) | SIGMAR1 | |
| SCHEMBL5254949 | 0.83 | KMT2A (1.00) | KMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL6298869 | 0.82 | KMT2A (0.74) | LMNAKMT2AMEN1ALDH1A1TSHR | |
| SCHEMBL23775435 | 0.81 | PKM (0.71) | LMNAPKMNPC1PKLRRAB9A | |
| SCHEMBL7027186 | 0.81 | KMT2A (0.68) | LMNAKMT2AMEN1PKMPKLR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | MERCK PATENT GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1246803-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT 2A? RECEPTOR ANTAGONISTS | MERCK PATENT GmbH (DE) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051469-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT2A RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130287-A1 | Piperidine and piperazine derivatives which function as 5-ht2a receptor antagonists | HTR2A, HTR1A, HTR5A | LMNA 1602/4885KMT2A 472/4885MEN1 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.